Please provide your email address to receive an email when new articles are posted on . In patients with moderate or severe ischemic stroke, a lower dose of IV tenecteplase yielded less favorable ...

Please provide your email address to receive an email when new articles are posted on . Administration of low-dose IV tenecteplase in the 4.5 to 24 hours after stroke symptom onset seemed to be safe ...

A study investigating a high dose (0.4 mg/kg) of the bolus thrombolytic tenecteplase in the treatment of patients with moderate to severe acute ischemic stroke was stopped prematurely because of ...

Making the switch from alteplase to tenecteplase for stroke thrombolysis can be done successfully when the appropriate preparations are taken, and it may improve patient outcomes, the experience of a ...

PRAGUE, Czech Republic — A 0.4-mg/kg bolus dose of tenecteplase (TNKase, Genentech) was associated with functional outcomes and safety similar to those seen with the standard of care, alteplase ...

When treating patients with acute ischemic stroke within 4.5 hours of symptom onset, tenecteplase provides noninferior outcomes compared with alteplase (Activase; Genentech), with similar safety, ...

Tenecteplase (TNKase) appeared feasible for thrombolysis in acute ischemic stroke in patients presenting up to 24 hours after symptom onset, a phase II trial suggested. The typical 0.25 mg/kg dose of ...

Tenecteplase is an effective thrombolytic agent for eligible patients with stroke who are treated within 4.5 hours after the onset of stroke. However, data regarding the effectiveness of tenecteplase ...

Japanese trial compared lytics for bridging before endovascular thrombectomy ...

Recent research has revealed compelling evidence supporting tenecteplase as a more effective treatment for ischemic strokes compared to traditional alteplase therapy. This discovery could mark a major ...

Thrombolytic agents, including tenecteplase, are generally used within 4.5 hours after the onset of stroke symptoms. Information on whether tenecteplase confers benefit beyond 4.5 hours is limited. We ...

The researchers observed no significant differences between tenecteplase and alteplase in terms of effectiveness or safety outcomes for the overall cohort after adjustment for covariates. HealthDay ...